First-line treatment for non-small cell lung cancer

被引：0
|
作者：
Pinn, Stephen
机构：
来源：
BRITISH JOURNAL OF HOSPITAL MEDICINE | 2011年 / 72卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [31] Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
    Matthew K. Wong
    Alvis I. Lo
    Bing Lam
    W. K. Lam
    Mary S. Ip
    James C. Ho
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 1023 - 1028
  • [32] Correction to: Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer
    Puneet Saxena
    Pawan Kumar Singh
    Prabhat Singh Malik
    Navneet Singh
    Current Treatment Options in Oncology, 2020, 21
  • [33] Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer
    Li, Tianhong
    Ma, Weijie
    Al-Obeidi, Ebaa
    CANCERS, 2024, 16 (13)
  • [34] Non-Small Cell Lung Cancer Patient Preferences for First-Line Treatment: A Discrete Choice Experiment
    MacEwan, Joanna P.
    Gupte-Singh, Komal
    Zhao, Lauren M.
    Reckamp, Karen L.
    MDM POLICY & PRACTICE, 2020, 5 (01)
  • [35] Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer
    Kubota, Tetsuya
    Okano, Yoshio
    Sakai, Mizu
    Takaoka, Masato
    Tsukuda, Tsukie
    Anabuki, Kazuki
    Kawase, Shigeo
    Miyamoto, Shintaro
    Ohnishi, Hiroshi
    Hatakeyama, Nobuo
    Machida, Hisanori
    Urata, Tomoyuki
    Yamamoto, Akira
    Ogushi, Fumitaka
    Yokoyama, Akihito
    ANTICANCER RESEARCH, 2016, 36 (01) : 307 - 312
  • [36] Analysis of continuous first-line treatment with docetaxel and carboplatin for advanced non-small cell lung cancer
    Aoki, Takuya
    Ebihara, Akinori
    Yogo, Yurika
    Suemasu, Keiichi
    Sakamaki, Fumio
    ONCOLOGY LETTERS, 2014, 7 (06) : 1771 - 1777
  • [37] Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer
    Myung Hee Chang
    Kyoung Ha Kim
    Hyun Jung Jun
    Hyo Song Kim
    Seong Yoon Yi
    Ji Eun Uhm
    Min Jae Park
    Do Hyoung Lim
    Sang Hoon Ji
    In Gyu Hwang
    Jeeyun Lee
    Yeon Hee Park
    Jin Seok Ahn
    Myung-ju Ahn
    Keunchil Park
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 917 - 924
  • [38] COST-EFFECTIVENESS OF CRIZOTINIB FOR FIRST-LINE TREATMENT IN NON-SMALL CELL LUNG CANCER IN ECUADOR
    Salcedo, E.
    Freire, V
    Cabezas, M.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S32 - S32
  • [39] Erlotinib as salvage treatment after failure to first-line gefitinib in Non-Small Cell Lung Cancer
    Wong, King Yan Matthew
    Lo, Alvis
    Lam, Jamie
    Lam, Bing
    Ip, Mary S.
    Ho, James C.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S719 - S719
  • [40] Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
    Wong, Matthew K.
    Lo, Alvis I.
    Lam, Bing
    Lam, W. K.
    Ip, Mary S.
    Ho, James C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (06) : 1023 - 1028
12345